{"ticker": {"uuid": "5cd77d1e-1e5b-40e6-8783-83a94da7de97", "symbol": "CRSP", "name": "Crispr Therapeutics AG", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "CRISPR Therapeutics Stock 6-Day Losing Spree: Stock Falls 18%", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQSnFpTHY5ZU01ZzhZZlQtZzZzekZxZHhYbkhzOXh0cDBfZ0ViZnF1bk5vTFZDTUQtNzNaNzlLRmRrS3JOalBJMVV2N0ZGWHZNYUgxbGxVVm5SejZwZjRSdk9jSmlyRW9IYmZqMlRuVFljVGlDQUF0YnA3YkE1dERPclM5aEpmdlEyTEw4N1J5RllGMktQZjYxelktdG9wM1RIYVZOTXU0Q1pnYk5HUFV1dFdFdllkVHpEbC1MOEpkcDBtd1FUdENpdUhn?oc=5", "source_name": "Trefis", "published_at": "2026-07-15T14:14:45+00:00", "published_display": "15 Jul 2026 14:14", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "6 Red Days In A Row: CRISPR Therapeutics Stock Is Down 18%", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPSkdmaXdOYXlPQm1vd2hhbEpvRXF1MXBTYlRrTlpaT1UwbDZPRS1mbGlyVzR3VENvaHppRG9BV2pEQTJvTlFCblpQUjNYVEQ0VmFPNVltWFZEeFp0U1V4aFRMeEpENkM2UUpwSFNuTkVIaXlHdTNKSEhCX3VmeFhCV2dJLVhpMksxWUxFWVhXRE5DVU1EYmkwWEI5Rlh3SDVoSVNyaUVheTBxVTJld0xsNjVncFFjN1Vy?oc=5", "source_name": "Trefis", "published_at": "2026-07-15T13:02:01+00:00", "published_display": "15 Jul 2026 13:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNRGtVMU94em43S21neEFpRzZ5ZmZPSWQxeU1RdDNpOTBvOFJHMkdvekd5NmhBdFZ5OEpVdWhBbURraDNxV2lXVG1hYnozSTNuYnlDOEJOX0cxWGFTRTFDQlFZNGhaSlJvM2RRY1ZqYzNvcFNkd3c0c0hncnRJanBMaTM4Ukd6QXVPdXZvSEVxVGZqbGNnSDBtNS1idXFQdGxfWHVJ?oc=5", "source_name": "Market source", "published_at": "2026-07-14T13:00:02+00:00", "published_display": "14 Jul 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Canal Insurance CO Purchases New Stake in CRISPR Therapeutics AG $CRSP", "summary": "Canal Insurance CO has acquired a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP) during the first quarter, purchasing 35,100 shares valued at approximately $1.67 million. Institutional investors and hedge funds now own 69.20% of the company's stock, with several firms increasi", "url": "https://www.marketbeat.com/instant-alerts/filing-canal-insurance-co-purchases-new-stake-in-crispr-therapeutics-ag-crsp-2026-07-14/", "source_name": "MarketBeat", "published_at": "2026-07-14T08:42:24", "published_display": "14 Jul 2026 08:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "CRISPR Therapeutics (CRSP) Stock Forecast & Analyst Ratings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "Moomoo", "published_at": "2026-07-12T11:31:57+00:00", "published_display": "12 Jul 2026 11:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics AG $CRSP Position Reduced by Sumitomo Mitsui Trust Group Inc.", "summary": "Sumitomo Mitsui Trust Group Inc. reduced its stake in CRISPR Therapeutics AG ($CRSP) by 5.3% in the first quarter of 2026, selling over 104,000 shares to hold 1.85 million shares valued at approximately $88.2 million. Despite this reduction and the company reporting a Q1 EPS of -", "url": "https://www.marketbeat.com/instant-alerts/filing-crispr-therapeutics-ag-crsp-position-reduced-by-sumitomo-mitsui-trust-group-inc-2026-07-11/", "source_name": "MarketBeat", "published_at": "2026-07-11T14:41:04", "published_display": "11 Jul 2026 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics(CRSP) Stock Options Chain | Quotes & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgJBVV95cUxQVVJjdUZXckVTbXFKTGg0T3ROd3dHRm1TVXo0UEI4UUVkYzJUSWsxaDZUY1laNWRIWWsxWl9DN3ZmUmVsdFU5anQ2VFVIdzZ0UVRWNkpvN2xKMEZhUjNJSzA1Y2d5bGdKRXJrdjFDcWx2eTlucUVJMVRXUXpXaGtQalpmZXFBZzlOQ1BKVWtRR0hLdERmSFg0cFUyLXN4cXVuWjNJeDF6eXUzWVhpZkNhcmVxR0d5am0yMjN2eFpaekRvU2R4MGNDMzZuZW1tR1hMbmtnbWJHVDE1Z25SY0pPTnJ6YjBLTGI4S2lkQUM5OFFpakxSOXBqNnF1WFVqNnk5TWlDWEg4b3JNLUJCd1NJQnhha1NXYzlBa2FJVHYyazJKdkxxbmhzSUh3?oc=5", "source_name": "Moomoo", "published_at": "2026-07-11T02:29:14+00:00", "published_display": "11 Jul 2026 02:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics AG (CRSP) Stock Dips While Market Gains: Key Facts", "summary": "CRISPR Therapeutics AG (CRSP) saw its stock dip by 5.31% while the broader market gained. Despite the recent dip, the company's shares have appreciated by 12.16% over the past month, outperforming its sector and the S&P 500. Analysts anticipate significant year-over-year growth i", "url": "https://finance.yahoo.com/markets/stocks/articles/crispr-therapeutics-ag-crsp-stock-215004723.html", "source_name": "Market source", "published_at": "2026-07-10T21:50:09", "published_display": "10 Jul 2026 21:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "3 Reasons to Buy CRISPR Therapeutics Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxPWi1mWjg4TzRWQjVkanFDQ2x5YzI0OFZpbWZsSVRHaDZsdzczX0hIalM4cU9xbHFjVkdJUXFCOXFsTUtFWDF2cVVMOXRlWElIRkxsU242LUFJck9JR29HbDJKTFhLcjdhTUJERlN3RVZ0VklNYXBvSG1YaE5zdnVUQlNlWDJjcU5HSjZtcW9R?oc=5", "source_name": "The Motley Fool", "published_at": "2026-07-10T18:00:00+00:00", "published_display": "10 Jul 2026 18:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics (CRSP) Short Interest & Short Float | Updated Jul 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMibkFVX3lxTE11bmE2YjA3ZmdRX0dqNlNzVl9JSkgtSEhiWjg5N2Y0ZUtrNWRkWG1NM0VoODBBbF9EZlhQdmVpbjFEc0k1Ty1nQWZmNXE2V0RybTNpNXdOTXVYN2R1OHNNd3pwUTkwRFk3ZHpXWGp3?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bank of America Securities Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)", "summary": "Bank of America Securities analyst Alec Stranahan reaffirmed a Buy rating for Crispr Therapeutics AG (CRSP) with an $83 price target. This follows a similar Buy rating by Piper Sandler. The company reported a quarterly revenue of $1.46 million and a GAAP net loss of $122.93 milli", "url": "https://www.theglobeandmail.com/investing/markets/stocks/CRSP/pressreleases/3180149/bank-of-america-securities-reaffirms-their-buy-rating-on-crispr-therapeutics-ag-crsp/", "source_name": "The Globe and Mail", "published_at": "2026-07-09T00:45:31", "published_display": "09 Jul 2026 00:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A New CRISPR \"DNA Shredder\" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics", "summary": "", "url": "https://finance.yahoo.com/m/5b48af79-132d-37f5-95b9-971c3a4bb8b3/a-new-crispr-%22dna-shredder%22.html", "source_name": "Motley Fool", "published_at": "2026-07-08T10:05:00+00:00", "published_display": "08 Jul 2026 10:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026?", "summary": "This article compares CRISPR Therapeutics and Viking Therapeutics, two biotechnology companies with different focuses: gene-editing and weight loss. While CRISPR Therapeutics has already launched its gene therapy Casgevy, Viking Therapeutics is a clinical-stage company with no cu", "url": "https://finance.yahoo.com/healthcare/articles/crispr-therapeutics-vs-viking-therapeutics-145652317.html", "source_name": "Market source", "published_at": "2026-07-08T00:45:31", "published_display": "08 Jul 2026 00:45", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/crispr-therapeutics-ag-crsp-declines-220001580.html", "source_name": "Zacks", "published_at": "2026-07-07T22:00:01+00:00", "published_display": "07 Jul 2026 22:00", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Over 2 Billion Reasons to Love CRISPR Therapeutics Right Now", "summary": "", "url": "https://finance.yahoo.com/m/9b17c5ef-4d61-387d-9285-d026e8079e85/over-2-billion-reasons-to.html", "source_name": "Motley Fool", "published_at": "2026-07-07T18:05:00+00:00", "published_display": "07 Jul 2026 18:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRSP - CRISPR Therapeutics AG Options", "summary": "This article provides detailed financial and stock option data for CRISPR Therapeutics AG (CRSP). It includes key metrics such as market cap, income, sales, EPS, various performance indicators, and insider/institutional ownership percentages, alongside recent trading performance ", "url": "https://finviz.com/quote.ashx?t=CRSP&ta=1&p=w&ty=oc&b=2&r=y2&ov=list_strike&s=70", "source_name": "Finviz", "published_at": "2026-07-06T16:39:45", "published_display": "06 Jul 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citizens reiterates CRISPR Therapeutics stock rating on label expansion potential", "summary": "Citizens maintained a Market Outperform rating and an $80.00 price target on CRISPR Therapeutics (NASDAQ:CRSP) shares, noting the company's stock is currently trading at $60.08, up 6.6% over the past week. The firm believes the expansion of the CASGEVY label to patients aged 2 or", "url": "https://www.investing.com/news/analyst-ratings/citizens-reiterates-crispr-therapeutics-stock-rating-on-label-expansion-potential-93CH-4775885", "source_name": "Investing.com", "published_at": "2026-07-06T10:13:53", "published_display": "06 Jul 2026 10:13", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does CRISPR Therapeutics\u2019 (CRSP) Russell Index Debut Quietly Reframe Its Biotech Growth Narrative?", "summary": "CRISPR Therapeutics (CRSP) was recently added to several Russell growth indexes, increasing its visibility to growth-focused investors and potentially influencing its investment narrative. While this inclusion may boost liquidity and market reactions, it doesn't fundamentally alt", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/does-crispr-therapeutics-crsp-russell-index-debut-quietly-re", "source_name": "Simply Wall Street", "published_at": "2026-07-05T21:13:53", "published_display": "05 Jul 2026 21:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics (CRSP) Price Forecast: Dual Breakout Targets Higher Prices", "summary": "CRISPR Therapeutics (CRSP) stock has experienced a significant breakout from a multi-week consolidation, confirmed by strong trading volume. This breakout from dual inverse head and shoulders patterns suggests a bullish reversal and potential for higher prices, with measured targ", "url": "https://www.fxempire.com/forecasts/article/crispr-therapeutics-crsp-price-forecast-dual-breakout-targets-higher-prices-1608316", "source_name": "FXEmpire", "published_at": "2026-07-03T21:05:39", "published_display": "03 Jul 2026 21:05", "sentiment": "positive", "sentiment_pct": 73, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics (CRSP) Stock Looks Stretched On Book Value Yet Reasonable On Broader Checks", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNTU9odzJ5OHZPV3lqdnVjN3dlZk5IZnpQQjN5MEpRN3Jnb2NCSFhfaldOa2dBNWJiU2twcnRBZ1NzLW5VWjhWOUU0dFo2eUVmaTVFZm9YeHd6ZGdZWk13My04bnhVTzVLVXFmUGhkSTRQM3dnbjhQLWxsNHJfWUtmZ2xJUE1ndHY4ajlQSlhoR1FqWTFwWm5sUUFfaXZ1UQ?oc=5", "source_name": "Market source", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know", "summary": "The article discusses why CRISPR Therapeutics AG (CRSP) is a heavily searched stock, focusing on its earnings estimates, revenue growth, and valuation. CRSP has outperformed the S&P 500 and its industry recently, but its Zacks Rank is a #3 (Hold) due to recent estimate changes an", "url": "https://uk.finance.yahoo.com/news/investors-heavily-search-crispr-therapeutics-130004846.html", "source_name": "Market source", "published_at": "2026-06-30T13:09:36", "published_display": "30 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in CRISPR Therapeutics AG Stocks", "summary": "This article lists various Exchange Traded Funds (ETFs) that hold shares of CRISPR Therapeutics AG (0VRQ). The list, sorted by market value, provides details such as the percentage weight of CRISPR in the ETF, the issuer, management style, focus, expense ratio, assets under manag", "url": "https://www.tradingview.com/symbols/LSE-0VRQ/etfs/", "source_name": "TradingView", "published_at": "2026-06-30T11:39:15", "published_display": "30 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics AG(NasdaqGM: CRSP) added to Russell 2000 Growth Benchmark", "summary": "CRISPR Therapeutics AG (NasdaqGM:CRSP), a gene-editing company, has been added to the Russell 2000 Growth Benchmark. The company's stock is currently trading at $56.35, with a positive year-to-date change. This inclusion is among several recent additions to various Russell benchm", "url": "https://www.marketscreener.com/news/crispr-therapeutics-ag-nasdaqgm-crsp-added-to-russell-2000-growth-benchmark-ce7f5fdede8ef124", "source_name": "marketscreener.com", "published_at": "2026-06-29T09:41:04", "published_display": "29 Jun 2026 09:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics AG(NasdaqGM: CRSP) added to Russell 3000E Growth Benchmark", "summary": "CRISPR Therapeutics AG (NasdaqGM: CRSP) has been added to the Russell 3000E Growth Benchmark. The company, a Switzerland-based gene editing firm, focuses on developing CRISPR/Cas9-based therapeutics to treat genetically defined diseases and engineer advanced cellular therapies. T", "url": "https://www.marketscreener.com/news/crispr-therapeutics-ag-nasdaqgm-crsp-added-to-russell-3000e-growth-benchmark-ce7f5fdeda8bf523", "source_name": "marketscreener.com", "published_at": "2026-06-29T04:39:35", "published_display": "29 Jun 2026 04:39", "sentiment": "positive", "sentiment_pct": 68, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What CRISPR Therapeutics (CRSP)'s Upgraded Revenue and EPS Forecasts Mean For Shareholders", "summary": "Analysts have recently raised revenue and EPS forecasts for CRISPR Therapeutics, suggesting increased confidence in the company's near-term gene-editing revenue potential, partly due to its partnership with Vertex. While this optimism could sharpen near-term catalysts, investors ", "url": "https://www.sahmcapital.com/news/content/what-crispr-therapeutics-crsps-upgraded-revenue-and-eps-forecasts-mean-for-shareholders-2026-06-28", "source_name": "Sahm", "published_at": "2026-06-28T10:40:16", "published_display": "28 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of CRISPR Therapeutics AG \u2013 DUS:1CG", "summary": "This article provides the \"Price to sales forward\" metric for CRISPR Therapeutics AG (DUS:1CG). The financial data is sourced from ICE Data Services and FactSet Research Systems Inc., with SEC filings provided by Quartr. The specific value for this metric is not detailed in the p", "url": "https://www.tradingview.com/symbols/DUS-1CG/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T21:10:32", "published_display": "27 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of CRISPR Therapeutics AG \u2013 NASDAQ:CRSP", "summary": "This article provides a brief overview of CRISPR Therapeutics AG (NASDAQ: CRSP) focusing on its price to sales forward metric. It also lists various financial and community features available on the TradingView platform for this stock. The content indicates that the market is cur", "url": "https://www.tradingview.com/symbols/NASDAQ-CRSP/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T16:40:56", "published_display": "27 Jun 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of CRISPR Therapeutics AG \u2013 NASDAQ:CRSP", "summary": "This article provides financial data specifically regarding the Enterprise Value to EBIT forward ratio for CRISPR Therapeutics AG (NASDAQ: CRSP). It indicates that the market was closed at the time of publication and presents a table showing the period, value, change, and percent", "url": "https://www.tradingview.com/symbols/NASDAQ-CRSP/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T10:40:16", "published_display": "27 Jun 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of CRISPR Therapeutics AG \u2013 NASDAQ:CRSP", "summary": "This article headline indicates a financial analysis for CRISPR Therapeutics AG (NASDAQ:CRSP), specifically focusing on its enterprise value to forward revenue ratio. The content appears to be a stub or an indication of where such financial data would be presented on the TradingV", "url": "https://www.tradingview.com/symbols/NASDAQ-CRSP/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T09:40:56", "published_display": "27 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of CRISPR Therapeutics AG \u2013 NASDAQ:CRSP", "summary": "This article provides the enterprise value to EBITDA forward for CRISPR Therapeutics AG (NASDAQ: CRSP). It indicates that the market was closed at the time of publication with no trades, and offers various financial and community data points related to the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-CRSP/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T06:10:34", "published_display": "27 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of CRISPR Therapeutics AG \u2013 DUS:1CG", "summary": "This article displays the \"Enterprise value to EBIT forward\" for CRISPR Therapeutics AG, listed under the stock symbol DUS:1CG on the Dusseldorf Stock Exchange. It indicates no trades occurred and provides a market closed status. The content is presented as a financial data point", "url": "https://www.tradingview.com/symbols/DUS-1CG/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T02:10:34", "published_display": "27 Jun 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is CRISPR Therapeutics (CRSP) Finally Ready for Prime Time After Casgevy's Initial Success", "summary": "CRISPR Therapeutics (CRSP) is transitioning into a commercial-stage biotech with the initial success of its gene-editing therapy, Casgevy, which exceeded Q4 2025 sales expectations and shows accelerating patient adoption. Beyond Casgevy, CRSP boasts a robust pipeline including th", "url": "https://www.kavout.com/market-lens/is-crispr-therapeutics-crsp-finally-ready-for-prime-time-after-casgevy-s-initial-success", "source_name": "Kavout | AI", "published_at": "2026-06-26T13:09:37", "published_display": "26 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics AG Actuals & Estimates (NASDAQ:CRSP)", "summary": "This article provides an overview of CRISPR Therapeutics AG (NASDAQ: CRSP) stock performance, financial data, and analyst forecasts. It covers the current stock price, historical highs and lows, market capitalization, and upcoming earnings reports, along with other financial metr", "url": "https://www.tradingview.com/symbols/NASDAQ-CRSP/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T20:09:37", "published_display": "25 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRSP Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast and price target for CRISPR Therapeutics AG (CRSP) stock, based on analyst opinions. It includes current stock performance metrics, historical price data, upcoming earnings report dates, and various financial figures such as market capitalization, ", "url": "https://www.tradingview.com/symbols/NASDAQ-CRSP/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T14:40:19", "published_display": "25 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics (CRSP) TD Cowen 46th Annual Health Care Conference Summary", "summary": "CRISPR Therapeutics presented its strategic shift towards a disease-focused model at the TD Cowen 46th Annual Health Care Conference, emphasizing cardiovascular and autoimmune franchises with expected data from six programs beyond Casgevy by mid-2027. The company detailed strong ", "url": "https://quartr.com/events/crispr-therapeutics-crsp-td-cowen-46th-annual-health-care-conference_3gICSnS8", "source_name": "Quartr", "published_at": "2026-06-21T18:11:29", "published_display": "21 Jun 2026 18:11", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics Stock - Weekly review against gene-editing peers", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOR2FLQmF1cGxiZVRRb0t2a0VqVjB4aF9zbEtxOUtTYWVoTWU1bGtsU0tkRXpzc01UREM0cGRtczBNZnZpOVVHWXB0U3VLR0ZxS0g1VjY5T1B6NEhNVmc3cFBYZUd0LTJFM0JKSzc5TS14Mmw1UFV3ZThHa2Y2MExpS2NaNUNfbTE0bDM5SUVFSEp6aFU4TzIzOGM0V0RaZGhzRmZZV2hkaVFla2lqa1FXd3hTM3pURUlyQnlPaDlCcjdLT1k?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-06-19T18:30:26+00:00", "published_display": "19 Jun 2026 18:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why CRISPR Therapeutics Stock Has Been on a Roller-Coaster Ride This Year", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxObzlXVVlBamlqTGNWQWpOdUZkVVNSQ2I0UFlTa1dWbGpkMndUQ2M0RDFSOW5lTFVrRTktdWZKZmwzUXp1YTNoOUVUeHZ1RFRmQ2xEeW1ha2lVSXYtY3pCcHViaGFrRkRrU2o3UUotTHlhOVRjaWdOc1VzYVg0aTBsTnYxc2xiRmRaRmlsQlJURkRDOUU0X1JzUQ?oc=5", "source_name": "The Motley Fool", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics AG (CRSP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey attempts to provide a revenue breakdown for CRISPR Therapeutics AG (CRSP), covering business segments, regional revenue, and profit contribution. However, it explicitly states that the relevant data for these categories has not yet been disclosed by t", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-crsp/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T17:39:22", "published_display": "17 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is CRISPR Therapeutics\u2019 (CRSP) ESOP Shelf Registration Quietly Redefining Its Long\u2011Term Risk\u2011Reward Profile?", "summary": "CRISPR Therapeutics (CRSP) recently filed a US$969.16 million ESOP-related shelf registration and amended its articles of association, prompting investors to re-evaluate the company's long-term risk-reward profile. While these moves reinforce equity-based compensation and balance", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/is-crispr-therapeutics-crsp-esop-shelf-registration-quietly", "source_name": "Simply Wall Street", "published_at": "2026-06-17T15:43:48", "published_display": "17 Jun 2026 15:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: enGene Holdings (ENGN) and Intellia Therapeutics (NTLA)", "summary": "Analysts have issued neutral ratings for enGene Holdings (ENGN) and Intellia Therapeutics (NTLA), indicating an evenly balanced outlook. Wells Fargo assigned a Hold rating to enGene Holdings with a $2.00 price target, while Bank of America Securities maintained a Hold rating on I", "url": "https://www.theglobeandmail.com/investing/markets/stocks/NTLA-Q/pressreleases/2509757/analysts-offer-insights-on-healthcare-companies-engene-holdings-engn-and-intellia-therapeutics-ntla/", "source_name": "The Globe and Mail", "published_at": "2026-06-17T10:10:48", "published_display": "17 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics stock (CH0334081137): Gene-editing hopes after recent updates on exa-cel and pip", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxQZDlfcFJsR0RabjdQcms5YTlMQ20zX0o3VGNKZzQxTno1aVFuaFNrelRicXlMci1PSE5Id0habHRIOURIbDYwLUVqRERKaGJLOTlKT3RpZ2RkUkVzZkpJTTZvZk1xd0ZHXy15eTc5eWZqaXdCR2xwWWU4aFlRVnlXcS1SemRYVEVPU1AyTTdsSG1fb1FlM0N0YWJlQ1ZoOHhrTjBtWkdOWlktSkppTHVQbVRpY0ZOR2FLQlhKaFJsdHI2QUZaSDIzMw?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its Stock Trading Nearly 40% Below the Wall Street Consensus?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNT1dxVEV5Y3kxWGV3dEUzYnVQYXpnbFJQVHg3TTh5TXJkRVhiNl9ob1ljbENmU19QVGFISDRPU09xb0dlbnEwT0ZnQWRpczZyQUdDbGlxdnhScnlWUG5zb2J3cTJQUjE4UzdqM25lRW5wUl83amFFbzNmMDBMV0Z1b1I5NXRHY2tHRWFUSkQ5UnZSNWstS2ow?oc=5", "source_name": "The Motley Fool", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics AG (CRSP): One of The most Shorted Mid Cap Stocks to Buy on Robust Gene Editing Pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOUUc1RmtYYUg0alNoUXpBQW0ycE1Pb3c2OTctVWExQnM2a3pWZDJMc1dYRmlrUFA1am1ZbXNlVlV3M0xYMDBFcEkyZ1h6dUYzNUEwV08wNm5BbGZoNFhHMWxHVHhkUjk4bklZejNudXpHY044TUtfVTlpd3ZoQ2U1clQxay1jYm5wanVWbUFJQi10eHZLTEladWdNLUk4RXE3SVE?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics stock (CH0334081137): Q1 loss and gene-editing focus shape valuation picture", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQTHZXZVNBVFY1dFlIbDEwTmx0YW1BRTNTdUM1ZElCSDNTSTgwaXJuTnRfdHh0emRGS0Y4bWtWTnpQemtsN05icTJCa0pjRERORW41cWJWMHk5TXB2eEdITnJaNDA0LThFdWVFWVF2c2YzcWJhNjJKekVyZl83ZXhJZG96RXQ4Z1p3TlZBY05OdDNHSUZoOURKNTl3c1RaZVZnWXZqUkR4Y3hIVWloMzRqVkowWThoSkZ4cHZBcjBJR0ZjLU90bG9R?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics Stock Is Absurdly Cheap -- Here's Why Analysts See 437% Upside Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxQUGhXTUQ5dlFka0xZcmU0Mm9PZGxXcDBfUHU0ZzhTd3Vac2tHSWJiTHp2Zmc2cmZTZ0E4QlJjSGswUmVoZFVKTVlpM0htUU94NkFPU0tJZWIxVnI0NWxobU5MbjhZM29LX0s5Z3E3VDBNeWwxekphQ3h6SVZQWFUtUVJfM1ZublhTLVhvdl9uWQ?oc=5", "source_name": "The Motley Fool", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is CRISPR Therapeutics (CRSP) Down 0.7% Since Last Earnings Report?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPd1NMQ2c2TGVlcnl5MlpPWGY3dm8tREYxMnQ5WjdKTUoySmRCR0c0S1oySnYzWGJfUGpxcEt2b3l1aHVDZEYtMS1JQ2U2WWFnY2dfa3RsMVMwLTl3QXBIUlEtNUhzRE9RUEN4WnBaRlBUYUZ5aHYzSXAyQ05zeEtUbVNQdHNkUGk3aHhKd1NpYWptZ3pVaWEzVDJ6QjhyMGdBNXF3WQ?oc=5", "source_name": "Market source", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "CRISPR Therapeutics stock (CH0334081137): Bernstein raises price target amid gene-editing momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQMlExRVhhSTlFN2ttYUVMUGNFM0p6S2VFQUpjSUttSlZ5bGhLejl6ZmhXUDdTRnJGYjdvcW0xWHoxNWVJSEwtWXpONVkzaWhlX1ptTDgzV3Rzc0NoWm5ZQUFONWNwNjFhemZ6cFhoU2VqUF9Zby1DbTU0TWM3SVpjX1JjQ2lsamxkZE12N0tPVDJrSG5MMVJyZ3pKVk5WMHVaQ0R3dEpPb0c2cGYxYTBYbXh3SjFmeGpwYUtSQ3RzeVFzbFJBTkE?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNdF82dF9qNnBfM1cwTTVOTTRBR0hQMEp5QTY5VUxqNTZ4MlMxS1ZPTHZyb0pRODhYdWpuWEZzcGpGc3Nmd0JMRzFoVWowRW1ESTVzaEIzem91Q0d0cWFyRUV2ZENfT0ROUDZqZ1RVeXBhUlhaU1VES2dpcVJCbllBbzB5cUc3a183WjQ5ajhTNDBUdTJQY2JqQ1FwMXRVVmYzNzR4U3pfYlZWTGpYZFE?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics' Q1 Loss Wider Than Expected, Sales Miss Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQMU5fLXp0bDlDX3RtdGxJTWxSRFIyMndqZ3VNeVFWTkF3NGxXRDB6V2ZUVkRacUVfNDk0QzRvOVlLblNkT2ZFZ1dkaC1qM1FtcDlEMExfN3lOVDRGM1hidzh5SGZsaDBWYmZsS0lUSHlVbjZwSGJDRm9uUTFGc2tMMzA1bEJPSVhTRXZySzdBWjNBZ3RxSmNwdDA5TXFWaW9KN0NWNi1zV3lwamY3bXZnRVFzWF9fODlLVm5adThDbGFEUQ?oc=5", "source_name": "TradingView", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNdHZaWndJdFlvODZCeE5fbWpobGhyVDZhZ0prWUtndXlVb2FKa2w2bjk2TDRmSnpzenRqNERORHdNaEhzZUdXMGluSndjX2E3SVpSSUZRLTNPRjRhbVViRjVCMk1sQ2xCYU1iVWhqendpLWJaZU1IaXRyZGMySHpBdG1RRW1oWXo0aW5RUHhGTWVVam8tTjVRSE5xNWxmQjg?oc=5", "source_name": "Market source", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Casgevy Revenue Surge and Clinical Advancements Bolster CRISPR Therapeutics\u2019 Market Position", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPQk1Jdl9RelEzd1dMQUxWd0ZpRGc2TUJsTFZJS2MtdlBHUWlWUXZkVUhYSzA3Tk96bHgzVlB3d01NWjBGWk9wSXdfalRZejgxZ0t5UHJzMmJVbzBDckhMQ3pCZGtneC1KTVFsdkNPR2FDeWtoOVdkNDloSzFXeXo2ZQ?oc=5", "source_name": "StocksToTrade", "published_at": "2026-01-22T08:00:00+00:00", "published_display": "22 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contrarius Global Equity Fund\u2019s Thoughts on CRISPR Therapeutics\u2019 (CRSP) Gene Editing Therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxQbjI1eThZdTRDaXNmTWF1S1RfbjFLTjlDMlBrVDF1MklxekQ5bGZYTHVQNlVWRGFmSHF6VlRYelkwQlE4TDV3YTYtcHdxUzBWMmhzSnRUejNMNTBsVjZPOXVqc2RYUkZ2LUJzVEpLR3NMOFZWVGJyb0U1Q2ZCLVZINFpiSGpnMDNsSG1Sbg?oc=5", "source_name": "Market source", "published_at": "2025-12-30T08:00:00+00:00", "published_display": "30 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "CRISPR Therapeutics Stock 6-Day Losing Spree: Stock Falls 18%", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQSnFpTHY5ZU01ZzhZZlQtZzZzekZxZHhYbkhzOXh0cDBfZ0ViZnF1bk5vTFZDTUQtNzNaNzlLRmRrS3JOalBJMVV2N0ZGWHZNYUgxbGxVVm5SejZwZjRSdk9jSmlyRW9IYmZqMlRuVFljVGlDQUF0YnA3YkE1dERPclM5aEpmdlEyTEw4N1J5RllGMktQZjYxelktdG9wM1RIYVZOTXU0Q1pnYk5HUFV1dFdFdllkVHpEbC1MOEpkcDBtd1FUdENpdUhn?oc=5", "source_name": "Trefis", "published_at": "2026-07-15T14:14:45+00:00", "published_display": "15 Jul 2026 14:14", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "6 Red Days In A Row: CRISPR Therapeutics Stock Is Down 18%", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPSkdmaXdOYXlPQm1vd2hhbEpvRXF1MXBTYlRrTlpaT1UwbDZPRS1mbGlyVzR3VENvaHppRG9BV2pEQTJvTlFCblpQUjNYVEQ0VmFPNVltWFZEeFp0U1V4aFRMeEpENkM2UUpwSFNuTkVIaXlHdTNKSEhCX3VmeFhCV2dJLVhpMksxWUxFWVhXRE5DVU1EYmkwWEI5Rlh3SDVoSVNyaUVheTBxVTJld0xsNjVncFFjN1Vy?oc=5", "source_name": "Trefis", "published_at": "2026-07-15T13:02:01+00:00", "published_display": "15 Jul 2026 13:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNRGtVMU94em43S21neEFpRzZ5ZmZPSWQxeU1RdDNpOTBvOFJHMkdvekd5NmhBdFZ5OEpVdWhBbURraDNxV2lXVG1hYnozSTNuYnlDOEJOX0cxWGFTRTFDQlFZNGhaSlJvM2RRY1ZqYzNvcFNkd3c0c0hncnRJanBMaTM4Ukd6QXVPdXZvSEVxVGZqbGNnSDBtNS1idXFQdGxfWHVJ?oc=5", "source_name": "Market source", "published_at": "2026-07-14T13:00:02+00:00", "published_display": "14 Jul 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Canal Insurance CO Purchases New Stake in CRISPR Therapeutics AG $CRSP", "summary": "Canal Insurance CO has acquired a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP) during the first quarter, purchasing 35,100 shares valued at approximately $1.67 million. Institutional investors and hedge funds now own 69.20% of the company's stock, with several firms increasi", "url": "https://www.marketbeat.com/instant-alerts/filing-canal-insurance-co-purchases-new-stake-in-crispr-therapeutics-ag-crsp-2026-07-14/", "source_name": "MarketBeat", "published_at": "2026-07-14T08:42:24", "published_display": "14 Jul 2026 08:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics (CRSP) Stock Forecast & Analyst Ratings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "Moomoo", "published_at": "2026-07-12T11:31:57+00:00", "published_display": "12 Jul 2026 11:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics AG $CRSP Position Reduced by Sumitomo Mitsui Trust Group Inc.", "summary": "Sumitomo Mitsui Trust Group Inc. reduced its stake in CRISPR Therapeutics AG ($CRSP) by 5.3% in the first quarter of 2026, selling over 104,000 shares to hold 1.85 million shares valued at approximately $88.2 million. Despite this reduction and the company reporting a Q1 EPS of -", "url": "https://www.marketbeat.com/instant-alerts/filing-crispr-therapeutics-ag-crsp-position-reduced-by-sumitomo-mitsui-trust-group-inc-2026-07-11/", "source_name": "MarketBeat", "published_at": "2026-07-11T14:41:04", "published_display": "11 Jul 2026 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics(CRSP) Stock Options Chain | Quotes & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgJBVV95cUxQVVJjdUZXckVTbXFKTGg0T3ROd3dHRm1TVXo0UEI4UUVkYzJUSWsxaDZUY1laNWRIWWsxWl9DN3ZmUmVsdFU5anQ2VFVIdzZ0UVRWNkpvN2xKMEZhUjNJSzA1Y2d5bGdKRXJrdjFDcWx2eTlucUVJMVRXUXpXaGtQalpmZXFBZzlOQ1BKVWtRR0hLdERmSFg0cFUyLXN4cXVuWjNJeDF6eXUzWVhpZkNhcmVxR0d5am0yMjN2eFpaekRvU2R4MGNDMzZuZW1tR1hMbmtnbWJHVDE1Z25SY0pPTnJ6YjBLTGI4S2lkQUM5OFFpakxSOXBqNnF1WFVqNnk5TWlDWEg4b3JNLUJCd1NJQnhha1NXYzlBa2FJVHYyazJKdkxxbmhzSUh3?oc=5", "source_name": "Moomoo", "published_at": "2026-07-11T02:29:14+00:00", "published_display": "11 Jul 2026 02:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics AG (CRSP) Stock Dips While Market Gains: Key Facts", "summary": "CRISPR Therapeutics AG (CRSP) saw its stock dip by 5.31% while the broader market gained. Despite the recent dip, the company's shares have appreciated by 12.16% over the past month, outperforming its sector and the S&P 500. Analysts anticipate significant year-over-year growth i", "url": "https://finance.yahoo.com/markets/stocks/articles/crispr-therapeutics-ag-crsp-stock-215004723.html", "source_name": "Market source", "published_at": "2026-07-10T21:50:09", "published_display": "10 Jul 2026 21:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "3 Reasons to Buy CRISPR Therapeutics Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxPWi1mWjg4TzRWQjVkanFDQ2x5YzI0OFZpbWZsSVRHaDZsdzczX0hIalM4cU9xbHFjVkdJUXFCOXFsTUtFWDF2cVVMOXRlWElIRkxsU242LUFJck9JR29HbDJKTFhLcjdhTUJERlN3RVZ0VklNYXBvSG1YaE5zdnVUQlNlWDJjcU5HSjZtcW9R?oc=5", "source_name": "The Motley Fool", "published_at": "2026-07-10T18:00:00+00:00", "published_display": "10 Jul 2026 18:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics (CRSP) Short Interest & Short Float | Updated Jul 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMibkFVX3lxTE11bmE2YjA3ZmdRX0dqNlNzVl9JSkgtSEhiWjg5N2Y0ZUtrNWRkWG1NM0VoODBBbF9EZlhQdmVpbjFEc0k1Ty1nQWZmNXE2V0RybTNpNXdOTXVYN2R1OHNNd3pwUTkwRFk3ZHpXWGp3?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bank of America Securities Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)", "summary": "Bank of America Securities analyst Alec Stranahan reaffirmed a Buy rating for Crispr Therapeutics AG (CRSP) with an $83 price target. This follows a similar Buy rating by Piper Sandler. The company reported a quarterly revenue of $1.46 million and a GAAP net loss of $122.93 milli", "url": "https://www.theglobeandmail.com/investing/markets/stocks/CRSP/pressreleases/3180149/bank-of-america-securities-reaffirms-their-buy-rating-on-crispr-therapeutics-ag-crsp/", "source_name": "The Globe and Mail", "published_at": "2026-07-09T00:45:31", "published_display": "09 Jul 2026 00:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A New CRISPR \"DNA Shredder\" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics", "summary": "", "url": "https://finance.yahoo.com/m/5b48af79-132d-37f5-95b9-971c3a4bb8b3/a-new-crispr-%22dna-shredder%22.html", "source_name": "Motley Fool", "published_at": "2026-07-08T10:05:00+00:00", "published_display": "08 Jul 2026 10:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026?", "summary": "This article compares CRISPR Therapeutics and Viking Therapeutics, two biotechnology companies with different focuses: gene-editing and weight loss. While CRISPR Therapeutics has already launched its gene therapy Casgevy, Viking Therapeutics is a clinical-stage company with no cu", "url": "https://finance.yahoo.com/healthcare/articles/crispr-therapeutics-vs-viking-therapeutics-145652317.html", "source_name": "Market source", "published_at": "2026-07-08T00:45:31", "published_display": "08 Jul 2026 00:45", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/crispr-therapeutics-ag-crsp-declines-220001580.html", "source_name": "Zacks", "published_at": "2026-07-07T22:00:01+00:00", "published_display": "07 Jul 2026 22:00", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Over 2 Billion Reasons to Love CRISPR Therapeutics Right Now", "summary": "", "url": "https://finance.yahoo.com/m/9b17c5ef-4d61-387d-9285-d026e8079e85/over-2-billion-reasons-to.html", "source_name": "Motley Fool", "published_at": "2026-07-07T18:05:00+00:00", "published_display": "07 Jul 2026 18:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRSP - CRISPR Therapeutics AG Options", "summary": "This article provides detailed financial and stock option data for CRISPR Therapeutics AG (CRSP). It includes key metrics such as market cap, income, sales, EPS, various performance indicators, and insider/institutional ownership percentages, alongside recent trading performance ", "url": "https://finviz.com/quote.ashx?t=CRSP&ta=1&p=w&ty=oc&b=2&r=y2&ov=list_strike&s=70", "source_name": "Finviz", "published_at": "2026-07-06T16:39:45", "published_display": "06 Jul 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citizens reiterates CRISPR Therapeutics stock rating on label expansion potential", "summary": "Citizens maintained a Market Outperform rating and an $80.00 price target on CRISPR Therapeutics (NASDAQ:CRSP) shares, noting the company's stock is currently trading at $60.08, up 6.6% over the past week. The firm believes the expansion of the CASGEVY label to patients aged 2 or", "url": "https://www.investing.com/news/analyst-ratings/citizens-reiterates-crispr-therapeutics-stock-rating-on-label-expansion-potential-93CH-4775885", "source_name": "Investing.com", "published_at": "2026-07-06T10:13:53", "published_display": "06 Jul 2026 10:13", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does CRISPR Therapeutics\u2019 (CRSP) Russell Index Debut Quietly Reframe Its Biotech Growth Narrative?", "summary": "CRISPR Therapeutics (CRSP) was recently added to several Russell growth indexes, increasing its visibility to growth-focused investors and potentially influencing its investment narrative. While this inclusion may boost liquidity and market reactions, it doesn't fundamentally alt", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/does-crispr-therapeutics-crsp-russell-index-debut-quietly-re", "source_name": "Simply Wall Street", "published_at": "2026-07-05T21:13:53", "published_display": "05 Jul 2026 21:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics (CRSP) Price Forecast: Dual Breakout Targets Higher Prices", "summary": "CRISPR Therapeutics (CRSP) stock has experienced a significant breakout from a multi-week consolidation, confirmed by strong trading volume. This breakout from dual inverse head and shoulders patterns suggests a bullish reversal and potential for higher prices, with measured targ", "url": "https://www.fxempire.com/forecasts/article/crispr-therapeutics-crsp-price-forecast-dual-breakout-targets-higher-prices-1608316", "source_name": "FXEmpire", "published_at": "2026-07-03T21:05:39", "published_display": "03 Jul 2026 21:05", "sentiment": "positive", "sentiment_pct": 73, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics (CRSP) Stock Looks Stretched On Book Value Yet Reasonable On Broader Checks", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNTU9odzJ5OHZPV3lqdnVjN3dlZk5IZnpQQjN5MEpRN3Jnb2NCSFhfaldOa2dBNWJiU2twcnRBZ1NzLW5VWjhWOUU0dFo2eUVmaTVFZm9YeHd6ZGdZWk13My04bnhVTzVLVXFmUGhkSTRQM3dnbjhQLWxsNHJfWUtmZ2xJUE1ndHY4ajlQSlhoR1FqWTFwWm5sUUFfaXZ1UQ?oc=5", "source_name": "Market source", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know", "summary": "The article discusses why CRISPR Therapeutics AG (CRSP) is a heavily searched stock, focusing on its earnings estimates, revenue growth, and valuation. CRSP has outperformed the S&P 500 and its industry recently, but its Zacks Rank is a #3 (Hold) due to recent estimate changes an", "url": "https://uk.finance.yahoo.com/news/investors-heavily-search-crispr-therapeutics-130004846.html", "source_name": "Market source", "published_at": "2026-06-30T13:09:36", "published_display": "30 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in CRISPR Therapeutics AG Stocks", "summary": "This article lists various Exchange Traded Funds (ETFs) that hold shares of CRISPR Therapeutics AG (0VRQ). The list, sorted by market value, provides details such as the percentage weight of CRISPR in the ETF, the issuer, management style, focus, expense ratio, assets under manag", "url": "https://www.tradingview.com/symbols/LSE-0VRQ/etfs/", "source_name": "TradingView", "published_at": "2026-06-30T11:39:15", "published_display": "30 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics AG(NasdaqGM: CRSP) added to Russell 2000 Growth Benchmark", "summary": "CRISPR Therapeutics AG (NasdaqGM:CRSP), a gene-editing company, has been added to the Russell 2000 Growth Benchmark. The company's stock is currently trading at $56.35, with a positive year-to-date change. This inclusion is among several recent additions to various Russell benchm", "url": "https://www.marketscreener.com/news/crispr-therapeutics-ag-nasdaqgm-crsp-added-to-russell-2000-growth-benchmark-ce7f5fdede8ef124", "source_name": "marketscreener.com", "published_at": "2026-06-29T09:41:04", "published_display": "29 Jun 2026 09:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics AG(NasdaqGM: CRSP) added to Russell 3000E Growth Benchmark", "summary": "CRISPR Therapeutics AG (NasdaqGM: CRSP) has been added to the Russell 3000E Growth Benchmark. The company, a Switzerland-based gene editing firm, focuses on developing CRISPR/Cas9-based therapeutics to treat genetically defined diseases and engineer advanced cellular therapies. T", "url": "https://www.marketscreener.com/news/crispr-therapeutics-ag-nasdaqgm-crsp-added-to-russell-3000e-growth-benchmark-ce7f5fdeda8bf523", "source_name": "marketscreener.com", "published_at": "2026-06-29T04:39:35", "published_display": "29 Jun 2026 04:39", "sentiment": "positive", "sentiment_pct": 68, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What CRISPR Therapeutics (CRSP)'s Upgraded Revenue and EPS Forecasts Mean For Shareholders", "summary": "Analysts have recently raised revenue and EPS forecasts for CRISPR Therapeutics, suggesting increased confidence in the company's near-term gene-editing revenue potential, partly due to its partnership with Vertex. While this optimism could sharpen near-term catalysts, investors ", "url": "https://www.sahmcapital.com/news/content/what-crispr-therapeutics-crsps-upgraded-revenue-and-eps-forecasts-mean-for-shareholders-2026-06-28", "source_name": "Sahm", "published_at": "2026-06-28T10:40:16", "published_display": "28 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of CRISPR Therapeutics AG \u2013 DUS:1CG", "summary": "This article provides the \"Price to sales forward\" metric for CRISPR Therapeutics AG (DUS:1CG). The financial data is sourced from ICE Data Services and FactSet Research Systems Inc., with SEC filings provided by Quartr. The specific value for this metric is not detailed in the p", "url": "https://www.tradingview.com/symbols/DUS-1CG/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T21:10:32", "published_display": "27 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of CRISPR Therapeutics AG \u2013 NASDAQ:CRSP", "summary": "This article provides a brief overview of CRISPR Therapeutics AG (NASDAQ: CRSP) focusing on its price to sales forward metric. It also lists various financial and community features available on the TradingView platform for this stock. The content indicates that the market is cur", "url": "https://www.tradingview.com/symbols/NASDAQ-CRSP/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T16:40:56", "published_display": "27 Jun 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of CRISPR Therapeutics AG \u2013 NASDAQ:CRSP", "summary": "This article provides financial data specifically regarding the Enterprise Value to EBIT forward ratio for CRISPR Therapeutics AG (NASDAQ: CRSP). It indicates that the market was closed at the time of publication and presents a table showing the period, value, change, and percent", "url": "https://www.tradingview.com/symbols/NASDAQ-CRSP/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T10:40:16", "published_display": "27 Jun 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of CRISPR Therapeutics AG \u2013 NASDAQ:CRSP", "summary": "This article headline indicates a financial analysis for CRISPR Therapeutics AG (NASDAQ:CRSP), specifically focusing on its enterprise value to forward revenue ratio. The content appears to be a stub or an indication of where such financial data would be presented on the TradingV", "url": "https://www.tradingview.com/symbols/NASDAQ-CRSP/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T09:40:56", "published_display": "27 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of CRISPR Therapeutics AG \u2013 NASDAQ:CRSP", "summary": "This article provides the enterprise value to EBITDA forward for CRISPR Therapeutics AG (NASDAQ: CRSP). It indicates that the market was closed at the time of publication with no trades, and offers various financial and community data points related to the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-CRSP/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T06:10:34", "published_display": "27 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of CRISPR Therapeutics AG \u2013 DUS:1CG", "summary": "This article displays the \"Enterprise value to EBIT forward\" for CRISPR Therapeutics AG, listed under the stock symbol DUS:1CG on the Dusseldorf Stock Exchange. It indicates no trades occurred and provides a market closed status. The content is presented as a financial data point", "url": "https://www.tradingview.com/symbols/DUS-1CG/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T02:10:34", "published_display": "27 Jun 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is CRISPR Therapeutics (CRSP) Finally Ready for Prime Time After Casgevy's Initial Success", "summary": "CRISPR Therapeutics (CRSP) is transitioning into a commercial-stage biotech with the initial success of its gene-editing therapy, Casgevy, which exceeded Q4 2025 sales expectations and shows accelerating patient adoption. Beyond Casgevy, CRSP boasts a robust pipeline including th", "url": "https://www.kavout.com/market-lens/is-crispr-therapeutics-crsp-finally-ready-for-prime-time-after-casgevy-s-initial-success", "source_name": "Kavout | AI", "published_at": "2026-06-26T13:09:37", "published_display": "26 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics AG Actuals & Estimates (NASDAQ:CRSP)", "summary": "This article provides an overview of CRISPR Therapeutics AG (NASDAQ: CRSP) stock performance, financial data, and analyst forecasts. It covers the current stock price, historical highs and lows, market capitalization, and upcoming earnings reports, along with other financial metr", "url": "https://www.tradingview.com/symbols/NASDAQ-CRSP/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T20:09:37", "published_display": "25 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRSP Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast and price target for CRISPR Therapeutics AG (CRSP) stock, based on analyst opinions. It includes current stock performance metrics, historical price data, upcoming earnings report dates, and various financial figures such as market capitalization, ", "url": "https://www.tradingview.com/symbols/NASDAQ-CRSP/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T14:40:19", "published_display": "25 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics (CRSP) TD Cowen 46th Annual Health Care Conference Summary", "summary": "CRISPR Therapeutics presented its strategic shift towards a disease-focused model at the TD Cowen 46th Annual Health Care Conference, emphasizing cardiovascular and autoimmune franchises with expected data from six programs beyond Casgevy by mid-2027. The company detailed strong ", "url": "https://quartr.com/events/crispr-therapeutics-crsp-td-cowen-46th-annual-health-care-conference_3gICSnS8", "source_name": "Quartr", "published_at": "2026-06-21T18:11:29", "published_display": "21 Jun 2026 18:11", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics Stock - Weekly review against gene-editing peers", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOR2FLQmF1cGxiZVRRb0t2a0VqVjB4aF9zbEtxOUtTYWVoTWU1bGtsU0tkRXpzc01UREM0cGRtczBNZnZpOVVHWXB0U3VLR0ZxS0g1VjY5T1B6NEhNVmc3cFBYZUd0LTJFM0JKSzc5TS14Mmw1UFV3ZThHa2Y2MExpS2NaNUNfbTE0bDM5SUVFSEp6aFU4TzIzOGM0V0RaZGhzRmZZV2hkaVFla2lqa1FXd3hTM3pURUlyQnlPaDlCcjdLT1k?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-06-19T18:30:26+00:00", "published_display": "19 Jun 2026 18:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why CRISPR Therapeutics Stock Has Been on a Roller-Coaster Ride This Year", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxObzlXVVlBamlqTGNWQWpOdUZkVVNSQ2I0UFlTa1dWbGpkMndUQ2M0RDFSOW5lTFVrRTktdWZKZmwzUXp1YTNoOUVUeHZ1RFRmQ2xEeW1ha2lVSXYtY3pCcHViaGFrRkRrU2o3UUotTHlhOVRjaWdOc1VzYVg0aTBsTnYxc2xiRmRaRmlsQlJURkRDOUU0X1JzUQ?oc=5", "source_name": "The Motley Fool", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics AG (CRSP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey attempts to provide a revenue breakdown for CRISPR Therapeutics AG (CRSP), covering business segments, regional revenue, and profit contribution. However, it explicitly states that the relevant data for these categories has not yet been disclosed by t", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-crsp/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T17:39:22", "published_display": "17 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is CRISPR Therapeutics\u2019 (CRSP) ESOP Shelf Registration Quietly Redefining Its Long\u2011Term Risk\u2011Reward Profile?", "summary": "CRISPR Therapeutics (CRSP) recently filed a US$969.16 million ESOP-related shelf registration and amended its articles of association, prompting investors to re-evaluate the company's long-term risk-reward profile. While these moves reinforce equity-based compensation and balance", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/is-crispr-therapeutics-crsp-esop-shelf-registration-quietly", "source_name": "Simply Wall Street", "published_at": "2026-06-17T15:43:48", "published_display": "17 Jun 2026 15:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: enGene Holdings (ENGN) and Intellia Therapeutics (NTLA)", "summary": "Analysts have issued neutral ratings for enGene Holdings (ENGN) and Intellia Therapeutics (NTLA), indicating an evenly balanced outlook. Wells Fargo assigned a Hold rating to enGene Holdings with a $2.00 price target, while Bank of America Securities maintained a Hold rating on I", "url": "https://www.theglobeandmail.com/investing/markets/stocks/NTLA-Q/pressreleases/2509757/analysts-offer-insights-on-healthcare-companies-engene-holdings-engn-and-intellia-therapeutics-ntla/", "source_name": "The Globe and Mail", "published_at": "2026-06-17T10:10:48", "published_display": "17 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics stock (CH0334081137): Gene-editing hopes after recent updates on exa-cel and pip", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxQZDlfcFJsR0RabjdQcms5YTlMQ20zX0o3VGNKZzQxTno1aVFuaFNrelRicXlMci1PSE5Id0habHRIOURIbDYwLUVqRERKaGJLOTlKT3RpZ2RkUkVzZkpJTTZvZk1xd0ZHXy15eTc5eWZqaXdCR2xwWWU4aFlRVnlXcS1SemRYVEVPU1AyTTdsSG1fb1FlM0N0YWJlQ1ZoOHhrTjBtWkdOWlktSkppTHVQbVRpY0ZOR2FLQlhKaFJsdHI2QUZaSDIzMw?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its Stock Trading Nearly 40% Below the Wall Street Consensus?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNT1dxVEV5Y3kxWGV3dEUzYnVQYXpnbFJQVHg3TTh5TXJkRVhiNl9ob1ljbENmU19QVGFISDRPU09xb0dlbnEwT0ZnQWRpczZyQUdDbGlxdnhScnlWUG5zb2J3cTJQUjE4UzdqM25lRW5wUl83amFFbzNmMDBMV0Z1b1I5NXRHY2tHRWFUSkQ5UnZSNWstS2ow?oc=5", "source_name": "The Motley Fool", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics AG (CRSP): One of The most Shorted Mid Cap Stocks to Buy on Robust Gene Editing Pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOUUc1RmtYYUg0alNoUXpBQW0ycE1Pb3c2OTctVWExQnM2a3pWZDJMc1dYRmlrUFA1am1ZbXNlVlV3M0xYMDBFcEkyZ1h6dUYzNUEwV08wNm5BbGZoNFhHMWxHVHhkUjk4bklZejNudXpHY044TUtfVTlpd3ZoQ2U1clQxay1jYm5wanVWbUFJQi10eHZLTEladWdNLUk4RXE3SVE?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics stock (CH0334081137): Q1 loss and gene-editing focus shape valuation picture", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQTHZXZVNBVFY1dFlIbDEwTmx0YW1BRTNTdUM1ZElCSDNTSTgwaXJuTnRfdHh0emRGS0Y4bWtWTnpQemtsN05icTJCa0pjRERORW41cWJWMHk5TXB2eEdITnJaNDA0LThFdWVFWVF2c2YzcWJhNjJKekVyZl83ZXhJZG96RXQ4Z1p3TlZBY05OdDNHSUZoOURKNTl3c1RaZVZnWXZqUkR4Y3hIVWloMzRqVkowWThoSkZ4cHZBcjBJR0ZjLU90bG9R?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics Stock Is Absurdly Cheap -- Here's Why Analysts See 437% Upside Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxQUGhXTUQ5dlFka0xZcmU0Mm9PZGxXcDBfUHU0ZzhTd3Vac2tHSWJiTHp2Zmc2cmZTZ0E4QlJjSGswUmVoZFVKTVlpM0htUU94NkFPU0tJZWIxVnI0NWxobU5MbjhZM29LX0s5Z3E3VDBNeWwxekphQ3h6SVZQWFUtUVJfM1ZublhTLVhvdl9uWQ?oc=5", "source_name": "The Motley Fool", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is CRISPR Therapeutics (CRSP) Down 0.7% Since Last Earnings Report?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPd1NMQ2c2TGVlcnl5MlpPWGY3dm8tREYxMnQ5WjdKTUoySmRCR0c0S1oySnYzWGJfUGpxcEt2b3l1aHVDZEYtMS1JQ2U2WWFnY2dfa3RsMVMwLTl3QXBIUlEtNUhzRE9RUEN4WnBaRlBUYUZ5aHYzSXAyQ05zeEtUbVNQdHNkUGk3aHhKd1NpYWptZ3pVaWEzVDJ6QjhyMGdBNXF3WQ?oc=5", "source_name": "Market source", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics stock (CH0334081137): Bernstein raises price target amid gene-editing momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQMlExRVhhSTlFN2ttYUVMUGNFM0p6S2VFQUpjSUttSlZ5bGhLejl6ZmhXUDdTRnJGYjdvcW0xWHoxNWVJSEwtWXpONVkzaWhlX1ptTDgzV3Rzc0NoWm5ZQUFONWNwNjFhemZ6cFhoU2VqUF9Zby1DbTU0TWM3SVpjX1JjQ2lsamxkZE12N0tPVDJrSG5MMVJyZ3pKVk5WMHVaQ0R3dEpPb0c2cGYxYTBYbXh3SjFmeGpwYUtSQ3RzeVFzbFJBTkE?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNdF82dF9qNnBfM1cwTTVOTTRBR0hQMEp5QTY5VUxqNTZ4MlMxS1ZPTHZyb0pRODhYdWpuWEZzcGpGc3Nmd0JMRzFoVWowRW1ESTVzaEIzem91Q0d0cWFyRUV2ZENfT0ROUDZqZ1RVeXBhUlhaU1VES2dpcVJCbllBbzB5cUc3a183WjQ5ajhTNDBUdTJQY2JqQ1FwMXRVVmYzNzR4U3pfYlZWTGpYZFE?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics' Q1 Loss Wider Than Expected, Sales Miss Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQMU5fLXp0bDlDX3RtdGxJTWxSRFIyMndqZ3VNeVFWTkF3NGxXRDB6V2ZUVkRacUVfNDk0QzRvOVlLblNkT2ZFZ1dkaC1qM1FtcDlEMExfN3lOVDRGM1hidzh5SGZsaDBWYmZsS0lUSHlVbjZwSGJDRm9uUTFGc2tMMzA1bEJPSVhTRXZySzdBWjNBZ3RxSmNwdDA5TXFWaW9KN0NWNi1zV3lwamY3bXZnRVFzWF9fODlLVm5adThDbGFEUQ?oc=5", "source_name": "TradingView", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNdHZaWndJdFlvODZCeE5fbWpobGhyVDZhZ0prWUtndXlVb2FKa2w2bjk2TDRmSnpzenRqNERORHdNaEhzZUdXMGluSndjX2E3SVpSSUZRLTNPRjRhbVViRjVCMk1sQ2xCYU1iVWhqendpLWJaZU1IaXRyZGMySHpBdG1RRW1oWXo0aW5RUHhGTWVVam8tTjVRSE5xNWxmQjg?oc=5", "source_name": "Market source", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Casgevy Revenue Surge and Clinical Advancements Bolster CRISPR Therapeutics\u2019 Market Position", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPQk1Jdl9RelEzd1dMQUxWd0ZpRGc2TUJsTFZJS2MtdlBHUWlWUXZkVUhYSzA3Tk96bHgzVlB3d01NWjBGWk9wSXdfalRZejgxZ0t5UHJzMmJVbzBDckhMQ3pCZGtneC1KTVFsdkNPR2FDeWtoOVdkNDloSzFXeXo2ZQ?oc=5", "source_name": "StocksToTrade", "published_at": "2026-01-22T08:00:00+00:00", "published_display": "22 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contrarius Global Equity Fund\u2019s Thoughts on CRISPR Therapeutics\u2019 (CRSP) Gene Editing Therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxQbjI1eThZdTRDaXNmTWF1S1RfbjFLTjlDMlBrVDF1MklxekQ5bGZYTHVQNlVWRGFmSHF6VlRYelkwQlE4TDV3YTYtcHdxUzBWMmhzSnRUejNMNTBsVjZPOXVqc2RYUkZ2LUJzVEpLR3NMOFZWVGJyb0U1Q2ZCLVZINFpiSGpnMDNsSG1Sbg?oc=5", "source_name": "Market source", "published_at": "2025-12-30T08:00:00+00:00", "published_display": "30 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 105, "total_relevant": 61, "sentiment_summary": {"positive": 19, "negative": 5, "neutral": 37, "score": 54, "total": 61, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 18.85, "count": 33}, {"event": "earnings", "label": "Earnings", "weight": 8.8, "count": 18}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 19, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 53.35, "latest_week": "2026-07-10", "one_week_move": -11.2, "four_week_move": 7.1, "twelve_week_move": -8.0, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.909417, "market_dynamics_buy_signal": false, "relative_strength": -18.097175, "fair_value_gap": 0.6, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 45.0161, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-11.2% over one week, +7.1% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 63, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 15}, {"label": "TradingView", "count": 11}, {"label": "The Motley Fool", "count": 4}, {"label": "Ad-hoc-news.de", "count": 4}, {"label": "MarketBeat", "count": 3}, {"label": "Trefis", "count": 2}, {"label": "Moomoo", "count": 2}, {"label": "The Globe and Mail", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 53}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 33}, {"label": "Earnings", "count": 18}, {"label": "Analyst action", "count": 5}, {"label": "Guidance", "count": 2}, {"label": "Balance sheet", "count": 2}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "53", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-11.2% over one week, +7.1% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "CRISPR Therapeutics Stock 6-Day Losing Spree: Stock Falls 18%"}], "updated_at": "2026-07-16T00:21:35.793916+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}